110 results about "Peptide inhibitor" patented technology

The invention provides an antibacterial peptide cAMP048 sourced from microorganisms in a deep sea environment and application of the antibacterial peptide cAMP048, and belongs to the technical field of peptide inhibitors. The antibacterial peptide cAMP048 has an amino acid sequence as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The antibacterial peptide can inhibit the growth of acinetobacter baumannii at 64 mu M, inhibit the growth of multi-drug-resistant acinetobacter baumannii and multi-drug-resistant enterococcus faecium at 128 mu M and inhibit the growth of escherichia coli, staphylococcus aureus and multi-drug-resistant klebsiella pneumoniae at 256 mu M. The antibacterial peptide can be used for preparing products with antibacterial and / or bactericidal performance, and can be applied to preparation of antibacterial and / or bactericidal products. Such as food, skin care products or medical supplies.

The invention discloses a polypeptide derived from deep sea microorganisms, and belongs to the technical field of peptide inhibitors. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1; the polypeptide has a bacteriostatic and / or bactericidal function. The polypeptide can inhibit the growth of acinetobacter baumannii at 8 [mu] M and inhibit the growth of escherichia coli and multi-drug-resistant acinetobacter baumannii at 16 [mu] M, and can be used for preparing products with bacteriostatic and / or bactericidal performance, such as food, daily necessities or medical products.

The present disclosure relates to compositions and methods, including Trim / inhibitors that find use in the treatment of disease, such as therapies for cancer, including cancers that are resistant to anti-checkpoint agents, infectious diseases and inflammatory diseases.

The application discloses a covalent polypeptide inhibitor targeting protein kinase A, a conjugate, a kit, a pharmaceutical composition and application. The general formula of the covalent polypeptide inhibitor is Z1-Seq-Z2; wherein Seq is an amino acid sequence; the C-terminal of Seq comprises a pseudo-substrate recognition motif recognized by protein kinase A, a non-natural amino acid with a covalent reaction group, and can be covalently crosslinked with a Cys200 residue on a catalytic subunit of protein kinase A; Z1 is selected from hydrogen, an acyl group, a fluorescent group, biotin, an isotopic tag or a biological ortho-reaction group; and Z2 is selected from a hydroxyl group, an amino group, a cell-penetrating peptide or a stabilization modification group. The covalent polypeptide inhibitor can strongly and irreversibly inhibit PKA activity, and can be used as an active probe to specifically label active PKA in a complex biological sample, and is used for biological research and drug development.

This disclosure features structurally-stabilized and / or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cysteine-reactive peptides in the treatment of BFL-1- and / or MCL-1-expressing or -dependent cancers or diseases of cellular excess (e.g., autoimmune or inflammatory conditions). Also provided are combination therapies comprising such structurally-stabilized and / or cysteine-reactive peptides and inhibitors of the DNA damage response pathway, such as an ATM kinase inhibitor, ATR kinase inhibitor, CHK1 / 2 inhibitor, or PARP inhibitor; or an inhibitor of MCL-1, or a selective inhibitor of BCL-2, or an inhibitor of BCL-2 / BCL-XL, for the treatment of BFL-1-expressing or -dependent cancers (e.g., AML), BFL-1 and MCL-1-expressing or -dependent cancers, or diseases of cellular excess (e.g., autoimmune or inflammatory conditions).

The inventors discovered that calcitonin gene-related peptide (CGRP) inhibitors reduce pain caused by bone fracture without impeding healing of the fracture. Accordingly, disclosed herein are methods for treating pain in a subject that has sustained a bone fracture, and the methods comprise administering a therapeutically effective amount of a CGRP inhibitor to the subject.

The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase – 1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.

Provide for herein are cyclic or linear peptides that bind HIV-1 capsid protein and inhibit HIV-1 capsid from assembling and / or disassembling. Further provided are methods of making said peptides and pharmaceutical compositions and methods for treating HIV infection.

The present invention relates to a peptide inhibitor of an interleukin-23 receptor and a use thereof. In particular, the present invention relates to peptide inhibitors of the interleukin-23 receptor, stereoisomers or pharmaceutically acceptable salts or solvates thereof, pharmaceutical compositions thereof, and uses of the peptide inhibitors in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

The present invention relates to compounds that are peptide inhibitors of the interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), psoriasis and psoriatic arthritis. The compound has good physical and chemical stability in the gastrointestinal tract.

Provided herein is a method of decreasing a-syn levels and / or decreasing a-syn toxicity in a cell, the method comprising contacting the cell with a charged multivesicular body protein 2B: a-synuclein (CHMP2B:a-syn) inhibitor and a method of inhibiting neural degeneration, the method comprising administering to a subject in need thereof a charged multivesicular body protein 2B: a-synuclein (CHMP2B:a-syn) inhibitor.

Provided are a novel peptide inhibitor of the interleukin-23 receptor, a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same, and the use of the peptide inhibitor in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

The present invention relates to a peptide inhibitor of interleukin-23 receptor, and a use thereof. In particular, it relates to a peptide inhibitor of interleukin-23 receptor, a stereoisomer, pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition thereof, and a use of the peptide inhibitor in treating or preventing diseases or conditions comprising inflammatory bowel disease, Crohn's disease, and psoriasis.

The present invention relates to a process for preparing a crystalline form of a monocyclic peptide compound, which is a peptide inhibitor of the interleukin-23 receptor (IL-23R), or a salt or solvate thereof. The crystalline forms are pharmaceutical compositions, methods and / or uses for the treatment of autoimmune inflammatory diseases and related conditions.

This disclosure relates to reversible affinity selection methods useful for the isolation and enrichment of covalent peptide inhibitors directly from large synthetic peptide libraries. Also disclosed herein are synthetic peptides for targeting HPV16 E6 and peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 protein.

The present disclosure relates to peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, methods and / or uses for the treatment of autoimmune inflammation and related diseases and disorders.

The present invention provides specific matrix metalloproteinase (MMP) polypeptide inhibitors and uses thereof in treating MMP-related diseases, in particular cancer, such as breast cancer and glioblastoma.

Uncontrolled secretion of extracellular matrix (ECM) proteins such as collagen can lead to excessive scarring and fibrosis and compromise tissue function. Despite the widespread occurrence of fibrotic diseases and scarring, effective therapies are lacking. The invention provides inhibitors of TANGO1 activity and methods of use thereof. In particular, the invention relates to peptide inhibitors capable of preventing TANGO1 heterodimerisation and / or homodimerisation and thereby prevent collagen export from the endoplasmic reticulum. The inhibitors of the invention are particularly useful for use in methods of treating fibrotic diseases, such as scleroderma.

The present disclosure relates to peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, methods and / or uses for treatment of autoimmune inflammation and related diseases and disorders.

The present invention discloses a PTP1B peptide inhibitor, BimBH3-12-F12A, having the following structural formula: #imgabs0#. This peptide mimetic compound is derived from the core 12-peptide of the BimBH3 domain, in which Phe (F) at position 12 is replaced by Ala (A). It is prepared using peptide solid-phase synthesis, and all amino acids in its structure are natural amino acids. The PTP1B peptide inhibitor, BimBH3-12-F12A, has significant PTP1B inhibitory activity and has potential application in the development of drugs for PTP1B-targeted diseases such as diabetes, cancer, and Alzheimer's disease.

The application discloses a polypeptide and application thereof, and belongs to the technical field of peptide inhibitors. The polypeptide has an amino acid sequence as shown in SEQ ID NO:1; the polypeptide has a bacteriostatic and / or bactericidal function. The polypeptide can inhibit the growth of Vibrio parahaemolyticus at 128 muM, can inhibit the growth of Vibrio harveyi, Vibrio alginolyticus and Vibrio anguillarum at 256 muM, and can inhibit the growth of Aeromonas hydrophila at 512 muM, and can be used for preparing products with bacteriostatic and / or bactericidal properties, such as food or aquaculture products.

The invention relates to washing and cleaning agents, in particular, liquid washing and cleaning agents, and particularly preferably liquid textile washing agents, comprising a) at least one protease, preferably in an amount of 0.0001 to 1 wt. %, relative to the total weight of the washing and cleaning agent, b) at least one peptide (peptidic inhibitor), preferably in a 0.5-, 1.0-, 1.5-, 2.0-, 2.5-, 3.0-, 3.5-, 4.0-, 4.5-, 5.0-, 10-, 15-, 18-, 20-, 25-, 27-, or 30-fold molar excess relative to the molarity of the protease used, preferably in a 15-, 18-, 20-, 25-, or 27-fold molar excess, the peptide preferably having a length of 50 to 200, preferably 55 to 190, and more preferably 60 to 180, amino acid functional groups, and c) at least one washing and cleaning agent ingredient, preferably in an amount of 0.01 to 99.9 wt. %, relative to the total weight of the washing and cleaning agent. Also included in the invention are the corresponding washing and cleaning processes, the use of the agents described herein, and the use of a peptidic inhibitor to improve the stability of a protease in washing or cleaning agents.

Synthetic peptides mimicking the nsp10 sequence in the region interacting with nsp16 capable of penetrating cell membranes and inhibiting SARS-CoV-2 replication for the treatment of moderate to severe COVID-19. The invention relates to peptides inhibiting SARS-CoV-2 replication, likely through inhibition of Methyltransferase complexes (NSP10 / NSP16 and NSP10 / NSP14). The peptide of the present invention, P3, contains sequences corresponding to amino acids 89-96 of the non-structural protein 10 (NSP10) of SARS-CoV-2, with the only Cysteine modified to a Methionine. This peptide was made based on two previous designs P1 and P2, which constituted the amino acids 68-96 of the NSP10 protein of SARS-CoV-2.

This disclosure provides peptides which have an affinity for the focal adhesion targeting (FAT) domain of focal adhesion kinase (FAK). In particular, the peptides are modified and derived from the sequence of the LD2 alpha helical domain of paxillin (e.g., LD2 peptides), the LD4 domain of paxillin (e.g., LD4 peptides), and CD8 peptides. These peptides are capable of blocking an interaction between paxillin and FAK, thereby inhibiting FAK activity related to FAK-paxillin interaction. The invention further provides uses for such peptides as therapeutics for the treatment of cancer and other diseases characterized with FAK activity and / or expression (e.g., fibrosis).

The present disclosure relates to compositions and methods, including Trim / inhibitors that find use in the treatment of disease, such as therapies for cancer, including cancers that are resistant to anti-checkpoint agents, infectious diseases and inflammatory diseases.

The present invention relates to methods for preparing crystalline forms of a monocyclic peptide compound, or salts or solvates thereof, which is a peptide inhibitor of the interleukin-23 receptor (IL-23R). The crystalline forms are useful in pharmaceutical compositions, methods and / or uses for treatment of autoimmune inflammation diseases and related disorders.

The present invention relates to a pharmaceutical composition containing a polypeptide inhibitor and a use of the pharmaceutical composition. The composition has good stability and drug dissolution rate; the product has controllable quality; and a preparation method has simple process, strong operability, good reproducibility, and is suitable for large-scale industrial production.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

The present invention relates to: a peptide inhibitor, which targets FOXO4-p53 interactions, for removing senescent cells; and a use thereof. The peptide inhibitor according to the present invention is designed on the basis of a p53 transactivation domain (TAD) sequence, thus exhibiting strong selectivity for senescent cells, has a synthesis cost due to being short and having an L-type amino acid configuration, and has the effect of efficiently interfering with FOXO4-p53 interactions despite being short and having an L-type amino acid configuration. Therefore, the peptide inhibitor according to the present invention is expected to be widely used in various health / medical fields requiring the removal of senescent cells.